Stay updated on Uproleselan with Chemotherapy for AML Clinical Trial
Sign up to get notified when there's something new on the Uproleselan with Chemotherapy for AML Clinical Trial page.

Latest updates to the Uproleselan with Chemotherapy for AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe ClinicalTrials.gov record for the terminated uproleselan AML trial is displayed, with details on its design, eligibility, outcomes, and locations, replacing a 403 error screen.SummaryDifference76%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA sitewide NIH notice says that agency content may use “Super Intelligence” in place of “Artificial Intelligence” during a transition. It appears above the page’s 403 error message.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier updates from v3.7.1 to v3.7.2 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, indicating restricted access to the requested study record.SummaryDifference17%

Stay in the know with updates to Uproleselan with Chemotherapy for AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Uproleselan with Chemotherapy for AML Clinical Trial page.